IL231951B - pam3cys-like stimulants and their use for the preparation of preparations - Google Patents

pam3cys-like stimulants and their use for the preparation of preparations

Info

Publication number
IL231951B
IL231951B IL231951A IL23195114A IL231951B IL 231951 B IL231951 B IL 231951B IL 231951 A IL231951 A IL 231951A IL 23195114 A IL23195114 A IL 23195114A IL 231951 B IL231951 B IL 231951B
Authority
IL
Israel
Prior art keywords
pam3cys
medicaments
manufacture
adjuvant compounds
adjuvant
Prior art date
Application number
IL231951A
Other languages
English (en)
Hebrew (he)
Other versions
IL231951A0 (en
Inventor
Antonius Ossendorp Ferdinand
Johannes Maria Melief Cornelis
Khan Selina
Viktorovitsj Filippov Dmitri
Arie Van Der Marel Gijsbert
Original Assignee
Isa Pharmaceuticals B V
Antonius Ossendorp Ferdinand
Johannes Maria Melief Cornelis
Khan Selina
Viktorovitsj Filippov Dmitri
Arie Van Der Marel Gijsbert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isa Pharmaceuticals B V, Antonius Ossendorp Ferdinand, Johannes Maria Melief Cornelis, Khan Selina, Viktorovitsj Filippov Dmitri, Arie Van Der Marel Gijsbert filed Critical Isa Pharmaceuticals B V
Publication of IL231951A0 publication Critical patent/IL231951A0/en
Publication of IL231951B publication Critical patent/IL231951B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IL231951A 2011-10-05 2014-04-03 pam3cys-like stimulants and their use for the preparation of preparations IL231951B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161543510P 2011-10-05 2011-10-05
NL2007536A NL2007536C2 (en) 2011-10-05 2011-10-05 Adjuvant compound.
US201261615566P 2012-03-26 2012-03-26
PCT/NL2012/050694 WO2013051936A1 (en) 2011-10-05 2012-10-04 Adjuvant compound

Publications (2)

Publication Number Publication Date
IL231951A0 IL231951A0 (en) 2014-05-28
IL231951B true IL231951B (en) 2019-08-29

Family

ID=48043964

Family Applications (1)

Application Number Title Priority Date Filing Date
IL231951A IL231951B (en) 2011-10-05 2014-04-03 pam3cys-like stimulants and their use for the preparation of preparations

Country Status (16)

Country Link
US (2) US9314521B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2763697B9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6099210B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102053699B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104244976B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2012319265B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014008214B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2886631C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA030741B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2952644T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL231951B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN03325A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX356028B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL2007536C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201401291XA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013051936A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX365465B (es) 2013-03-21 2019-06-04 Sanofi Aventis Deutschland Sintesis de productos peptidicos que contienen imida ciclica.
HK1219477A1 (zh) 2013-03-21 2017-04-07 Sanofi-Aventis Deutschland Gmbh 合成含有乙内酰脲的肽产物
EP3604271A1 (en) 2013-06-28 2020-02-05 Auckland Uniservices Limited Peptides for amino acid and peptide conjugates and conjugation process
EP3148566B1 (en) 2014-06-02 2024-04-03 ISA Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
WO2016103192A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
IL298653A (en) 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
AU2017223267B2 (en) 2016-02-26 2021-07-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
KR20190020098A (ko) 2016-06-20 2019-02-27 아이에스에이 파마슈티컬즈 비.브이. 펩타이드 백신의 제형
IL263616B2 (en) 2016-07-07 2025-01-01 Univ Leland Stanford Junior Antibody-adjuvant conjugates
BR112019020853A2 (pt) 2017-04-04 2020-05-12 Avidea Technologies, Inc. Vacinas à base de peptídeo, métodos de fabricação e usos das mesmas para induzir uma resposta imune
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
KR20220004634A (ko) 2019-03-15 2022-01-11 볼트 바이오테라퓨틱스 인코퍼레이티드 Her2를 표적으로 하는 면역접합체
US20230242590A1 (en) 2019-12-07 2023-08-03 Isa Pharmaceuticals B.V. Treatment of diseases related to hepatitis b virus
EP4100051A2 (en) 2020-02-07 2022-12-14 ISA Pharmaceuticals B.V. Treatment of hpv-related diseases
WO2021214297A1 (en) 2020-04-23 2021-10-28 Isa Pharmaceuticals B.V. Immunization against sars-cov-related diseases
EP4370903A1 (en) 2021-07-12 2024-05-22 ISA Pharmaceuticals B.V. Improved substance quantification in complex mixtures
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
AU2023361181A1 (en) 2022-10-13 2025-05-22 Isabella Pharma B.V. Modified long peptides suitable for use in immunisation
WO2024149888A1 (en) 2023-01-12 2024-07-18 Isa Pharmaceuticals B.V. Improved lipopeptide quantification
WO2025008085A1 (en) 2023-07-05 2025-01-09 Isa Pharmaceuticals B.V. Immunotherapy for the treatment of prame-expressing cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485094D1 (de) * 1983-01-25 1991-10-31 Ciba Geigy Ag Neue peptidderivate.
DE3937412A1 (de) * 1989-11-10 1991-05-16 Hoechst Ag Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001000828A2 (en) 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
NL1012739C2 (nl) 1999-07-29 2001-01-30 Maasland Nv Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer.
AU2002219711B8 (en) 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
MXNL04000056A (es) 2004-06-30 2006-01-11 Mario Alberto Aguilera Rico Sistema de construccion terra acero.
JP2010500407A (ja) * 2006-08-14 2010-01-07 サイモン・エル・エル・シー Hiv−1の複数の株及びサブタイプを治療及び予防するための組成物及び方法
CN106220721B (zh) 2007-03-26 2020-04-07 莱顿大学医学中心附属莱顿教学医院 Prame衍生的肽以及包括该肽的免疫原组合物
WO2008147186A1 (en) 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc P53 peptide vaccine
ES2411059T3 (es) 2007-05-31 2013-07-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Epítopos de HPV objetivos de células T que infiltran malignidades cervicales para su uso en vacunas
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
EA031379B1 (ru) * 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний

Also Published As

Publication number Publication date
US9770506B2 (en) 2017-09-26
EA030741B1 (ru) 2018-09-28
MX356028B (es) 2018-05-09
NL2007536C2 (en) 2013-04-08
CA2886631C (en) 2019-06-11
CN104244976A (zh) 2014-12-24
US20150104473A1 (en) 2015-04-16
IL231951A0 (en) 2014-05-28
BR112014008214A2 (pt) 2017-06-13
BR112014008214B1 (pt) 2022-07-05
MX2014004114A (es) 2014-10-17
WO2013051936A1 (en) 2013-04-11
SG11201401291XA (en) 2014-05-29
EA201490709A1 (ru) 2014-09-30
ES2952644T3 (es) 2023-11-02
IN2014DN03325A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-06-26
WO2013051936A9 (en) 2013-09-12
AU2012319265A1 (en) 2014-05-22
KR102053699B1 (ko) 2019-12-09
US20160250325A1 (en) 2016-09-01
CA2886631A1 (en) 2013-04-11
EP2763697C0 (en) 2023-06-07
AU2012319265B2 (en) 2016-10-13
EP2763697B1 (en) 2023-06-07
NZ623869A (en) 2015-11-27
EP2763697B8 (en) 2023-07-12
JP6099210B2 (ja) 2017-03-22
EP2763697B9 (en) 2023-10-04
KR20140093673A (ko) 2014-07-28
JP2014530808A (ja) 2014-11-20
EP2763697A1 (en) 2014-08-13
US9314521B2 (en) 2016-04-19
CN104244976B (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
IL231951B (en) pam3cys-like stimulants and their use for the preparation of preparations
IL269054A (en) A pharmaceutical preparation containing tesimaltone for use in the treatment of 24-NON
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
PL2934404T3 (pl) Elastyczny laminat i sposób wytwarzania elastycznego laminatu
IL229844B (en) Anti-psgl-1 antibodies and their use
GB201120993D0 (en) Novel compounds and their use in therapy
ZA201403372B (en) Therapeutic agents and uses thereof
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
EP2718283A4 (en) INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
IL231082A0 (en) Pyrimido-pyridazinone compounds and their use
EP2840938A4 (en) THERAPEUTIC CUSHION
IL233825A (en) H1-indazole-3-carboxamide compounds, preparations containing them and their use in the preparation of medicines
ZA201400558B (en) Methods for the production of a cosmetic composition comprising leukolectin and uses thereof
GB201111775D0 (en) Compounds and uses thereof
SG10201604468QA (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
AU2011904672A0 (en) Therapeutic Compounds and Uses Thereof
GB201121726D0 (en) Compounds and uses thereof
GB201121551D0 (en) Compounds and uses thereof
AU2012904991A0 (en) Therapeutic Compounds and Uses Thereof
GB201005712D0 (en) Medicaments and their manufacture
GB201104872D0 (en) New compounds and medical uses
GB201104875D0 (en) New compounds and medical uses
GB201102215D0 (en) Inventions and therapy
GB201102222D0 (en) Inventions and therapy

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed